ClinicalTrials.gov record
Recruiting Phase 3 Interventional

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

ClinicalTrials.gov ID: NCT06097728

Public ClinicalTrials.gov record NCT06097728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (eVOLVE-Meso)

Study identification

NCT ID
NCT06097728
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
825 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Cisplatin Drug
  • Ipilimumab Drug
  • Nivolumab Drug
  • Pemetrexed Drug
  • Volrustomig Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 8, 2023
Primary completion
Nov 18, 2027
Completion
Nov 15, 2028
Last update posted
Apr 27, 2026

2023 – 2028

United States locations

U.S. sites
24
U.S. states
16
U.S. cities
20
Facility City State ZIP Site status
Research Site Phoenix Arizona 85054 Withdrawn
Research Site Duarte California 91010 Withdrawn
Research Site Santa Rosa California 95403 Recruiting
Research Site Aurora Colorado 80045 Recruiting
Research Site Jacksonville Florida 32224 Recruiting
Research Site Atlanta Georgia 30322 Recruiting
Research Site Chicago Illinois 60637 Recruiting
Research Site Baltimore Maryland 21231 Recruiting
Research Site Rochester Minnesota 55905 Recruiting
Research Site St Louis Missouri 63110 Recruiting
Research Site East Brunswick New Jersey 08816 Withdrawn
Research Site Commack New York 11725 Recruiting
Research Site Valhalla New York 10595 Recruiting
Research Site Cleveland Ohio 44111 Withdrawn
Research Site Cleveland Ohio 44124 Withdrawn
Research Site Cleveland Ohio 44195 Withdrawn
Research Site Columbus Ohio 43210 Recruiting
Research Site Independence Ohio 44131 Withdrawn
Research Site Portland Oregon 97213 Recruiting
Research Site Portland Oregon 97225 Recruiting
Research Site Portland Oregon 97239 Withdrawn
Research Site Philadelphia Pennsylvania 19104 Recruiting
Research Site Houston Texas 77030 Recruiting
Research Site Fairfax Virginia 22031 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 154 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06097728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 27, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06097728 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →